List of Excipients in Branded Drug NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE SINUS AND COLD

Generic Drugs Containing NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE SINUS AND COLD

Company	Ingredient	NDC	Excipient
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-816	CROSCARMELLOSE SODIUM
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-816	FERRIC OXIDE YELLOW
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-816	HYPROMELLOSE
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-816	HYPROMELLOSE 2208
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-816	HYPROMELLOSE 2910
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-816	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE SINUS AND COLD?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE YELLOW
1	HYPROMELLOSE
1	HYPROMELLOSE 2208
1	HYPROMELLOSE 2910
1	LACTOSE MONOHYDRATE

Excipient Strategy and Commercial Opportunities for Naproxen Sodium and Pseudoephedrine Hydrochloride Sinus and Cold Products

Last updated: August 6, 2026

Naproxen sodium and pseudoephedrine hydrochloride products combine a long-acting nonsteroidal anti-inflammatory drug with a nasal decongestant. The principal commercial opportunity is an orally administered, 12-hour tablet that delivers naproxen sodium for pain and fever while releasing pseudoephedrine hydrochloride over an extended period. Excipient selection determines release control, tablet size, manufacturability, stability, swallowability, and the ability to differentiate from established OTC products.

What is the active pharmaceutical ingredient profile?

The combination normally uses:

Component	Typical role	Representative strength
Naproxen sodium	Analgesic, antipyretic, anti-inflammatory	220 mg
Pseudoephedrine hydrochloride	Nasal decongestant	120 mg extended release
Dosage form	Oral extended-release tablet	12-hour dosing

The combination addresses sinus pressure, nasal congestion, headache, minor body aches, and fever associated with colds and sinus symptoms. The 220 mg naproxen sodium strength corresponds to the standard OTC naproxen sodium dose. Pseudoephedrine hydrochloride is commonly formulated as a 12-hour product at 120 mg per tablet.[1]

Naproxen sodium is highly water soluble relative to naproxen but can create formulation and stability issues because of its ionic character, alkaline microenvironment, and relatively high dose. Pseudoephedrine hydrochloride is also water soluble. A conventional immediate-release blend would therefore risk rapid pseudoephedrine release unless the formulation uses a matrix, coating, multiparticulate system, or other release-control mechanism.

What excipient strategy is required for a 12-hour combination tablet?

The core strategy is to separate the formulation functions even when both actives are compressed into one tablet. The excipient system must provide controlled pseudoephedrine release without impairing naproxen sodium dissolution.

Release-controlling excipients

Hydrophilic polymers are the most practical platform for a once- or twice-daily tablet. Suitable candidates include:

• Hypromellose, including controlled-viscosity grades
• Hydroxypropyl cellulose
• Polyethylene oxide
• Carbomers or other high-viscosity polymers, subject to compatibility and processing requirements

Upon hydration, the polymer forms a gel layer that slows diffusion and erosion. Polymer grade, particle size, compression force, and tablet porosity determine the release profile. A commercial formulation can use a lower-viscosity polymer for earlier release and a higher-viscosity grade for terminal control.

A multilayer tablet can allocate one layer to rapid naproxen sodium release and another to extended pseudoephedrine release. This approach provides more control than a homogeneous matrix but increases tooling, process validation, and manufacturing cost.

Fillers and compression aids

Microcrystalline cellulose is a conventional filler and dry binder for direct compression. Lactose, mannitol, dibasic calcium phosphate, and coprocessed excipients can provide alternative density, flow, and mouthfeel profiles.

The choice depends on the manufacturing process:

Manufacturing objective	Suitable excipient direction
Direct compression	Microcrystalline cellulose, coprocessed cellulose, colloidal silicon dioxide
Wet granulation	Lactose, povidone, starch derivatives
High tablet hardness	Microcrystalline cellulose, dibasic calcium phosphate, dry binders
Smaller tablet size	High-density fillers and optimized granulation
Reduced sticking	Colloidal silicon dioxide, magnesium stearate optimization

The 340 mg combined active load creates a substantial tablet-size constraint before excipients, coatings, and overages are added. High-density excipients and optimized granulation can improve swallowability and reduce packaging volume.

Lubricants and glidants

Magnesium stearate is widely used but can retard wetting and dissolution when over-lubrication occurs. The risk is material in a formulation where pseudoephedrine release must meet a defined extended-release profile.

Colloidal silicon dioxide can improve powder flow and reduce die-filling variability. Sodium stearyl fumarate may be evaluated where magnesium stearate creates dissolution or process concerns. Lubricant concentration and blending time should be treated as critical process parameters.

Film-coating excipients

A film coating can provide:

• Color and brand identification
• Improved swallowability
• Reduced friability
• Moisture protection
• Light protection
• Product differentiation

Typical coating systems use hypromellose or polyvinyl alcohol, plasticizers such as polyethylene glycol, and pigments such as titanium dioxide or iron oxides. The coating should not become the primary release-control mechanism unless the product is designed and validated as a coated extended-release system.

Taste and mouthfeel control

Taste is less commercially important for a swallowed tablet than for a liquid or orally disintegrating product. It becomes important if a chewable, mini-tablet, powder, or rapidly dispersible format is developed.

Naproxen sodium and pseudoephedrine hydrochloride can produce strong and potentially unpleasant taste profiles. Commercial approaches include:

• Polymer taste-masking coatings
• Ion-exchange resin complexes
• Lipid barriers
• Sweetener and flavor systems
• Microencapsulation

For an adult swallowable tablet, these technologies may add cost without a corresponding benefit unless they enable a smaller tablet, chewable format, or pediatric product.

Which excipients are most commercially attractive?

The strongest excipient opportunities are those that improve release control, stability, production efficiency, or tablet size without creating a new regulatory burden.

Excipient technology	Commercial value	Main development issue
High-viscosity hypromellose matrix	Established 12-hour release platform	Dose dumping and polymer-level optimization
Polyethylene oxide matrix	Strong extended-release control	Oxidative stability and processing sensitivity
Coprocessed filler-binder	Better flow and compression	Supplier qualification and cost
Low-moisture excipient system	Improved stability	Flow and electrostatic behavior
Functional film coating	Branding and swallowability	Coating uniformity and moisture transfer
Ion-exchange resin complex	Taste masking and abuse-resistance potential	Added complexity and dissolution validation
Multilayer tablet	Independent release profiles	Higher capital and process complexity
Multiparticulate capsule or sachet	Flexible release and dose design	Packaging, capsule fill, and cost

A high-viscosity hypromellose matrix remains the lowest-risk development path for a conventional 12-hour tablet. Multilayer and multiparticulate systems offer more differentiation but generally require stronger commercial justification.

What formulation patents protect naproxen sodium and pseudoephedrine products?

For legacy OTC combination products, broad composition-of-matter patents for naproxen sodium and pseudoephedrine hydrochloride are generally not the primary commercial barrier. Both active ingredients have long histories of pharmaceutical use, and the combination category is mature.

Potentially relevant protection can instead arise from:

• Extended-release matrix architecture
• Multilayer tablet design
• Coating and barrier systems
• Specific dissolution profiles
• Abuse-deterrent or tamper-resistant formats
• Manufacturing processes
• Stability-enhancing excipient combinations
• Method-of-use claims
• Brand trademarks and trade dress

A patent-by-patent freedom-to-operate conclusion cannot be made from the drug name alone. The product should be screened across U.S. Patent and Trademark Office records, FDA product databases, Orange Book listings where applicable, and litigation databases before launch.

For a mature OTC product, trade secrets may have greater practical value than patent claims. Polymer grades, granulation endpoints, coating parameters, dissolution specifications, and scale-up controls can be difficult to replicate even when the qualitative ingredient list is public.

What is the FDA regulatory and Orange Book status?

The product category is regulated as an OTC analgesic-decongestant combination. Naproxen sodium is covered by the FDA OTC monograph framework for internal analgesic, antipyretic, and antirheumatic products. Pseudoephedrine products are subject to decongestant requirements and additional federal controls because pseudoephedrine is a regulated precursor chemical.[2][3]

Key regulatory constraints include:

• Required labeling for analgesic, gastrointestinal, cardiovascular, renal, and hypertension risks
• Pseudoephedrine sales restrictions and purchase-logging requirements
• Extended-release dissolution and stability testing
• Drug-drug interaction and contraindication language
• Packaging controls appropriate for OTC use
• Child-resistant packaging requirements where applicable
• Manufacturing under current good manufacturing practice requirements

The Orange Book is most relevant when the product is marketed under an approved NDA or when an abbreviated application references an NDA. Monograph-compliant OTC products do not rely on Orange Book patent certifications in the same manner as prescription products. A current Orange Book and Drugs@FDA review is required to determine whether a specific branded product has an active NDA listing, patent listing, or exclusivity entry.[4][5]

When does naproxen sodium and pseudoephedrine lose exclusivity?

The active ingredients are long off-patent. Commercial exclusivity is therefore more likely to depend on brand rights, retailer relationships, regulatory positioning, formulation know-how, and distribution than on basic active-ingredient patents.

For a new formulation, potential exclusivity could arise from:

Protection type	Typical commercial function
New drug application exclusivity	Regulatory protection tied to an approved innovation
Formulation patent	Protects release architecture or excipient system
Method-of-use patent	Protects a defined therapeutic use or regimen
Trademark	Protects product name and brand recognition
Trade dress	Protects packaging and visual identity
Trade secret	Protects manufacturing and process parameters

Paragraph IV challenges are more relevant to an NDA-based extended-release product than to a standard monograph product. A generic applicant would need to identify the regulatory pathway and listed patents associated with the reference product. For a monograph product, a competitor may be able to enter through a compliant OTC product without making a Paragraph IV certification.

What generic entry risks exist?

The entry risk is high at the ingredient level and moderate at the finished-product level.

Ingredient-level risk

Naproxen sodium and pseudoephedrine hydrochloride are widely available active ingredients. Multiple manufacturers can source them, reducing API exclusivity risk.

Formulation-level risk

The main technical barrier is reproducing the pseudoephedrine release profile while maintaining acceptable naproxen sodium dissolution. A competitor must demonstrate:

• Extended-release performance
• Absence of dose dumping
• Batch-to-batch dissolution consistency
• Stability through shelf life
• Mechanical robustness
• Adequate content uniformity
• Acceptable tablet size and swallowability

Commercial entry scenarios

Entry scenario	Likely impact
Private-label monograph product	Rapid price competition
Authorized generic or licensed product	Lower launch risk and retailer access
Different-strength product	Partial substitution, limited direct overlap
Separate naproxen and pseudoephedrine products	More flexible dosing but lower convenience
Multisymptom cold product	Broader symptom coverage, higher interaction burden
Premium extended-release product	Potential margin defense through convenience

Pseudoephedrine availability creates a separate supply and compliance risk. A product may be technically substitutable but commercially constrained by purchase limits, retail controls, and retailer-specific policies.

How strong is the patent estate?

The patent estate for the active ingredients is weak because of their age. A modern formulation estate could be moderate if it covers a technically narrow but commercially important release system.

Patent strength should be assessed against five factors:

1. Whether claims cover the commercial tablet rather than a broad genus.
2. Whether the claims require a specific polymer, ratio, layer, coating, or dissolution profile.
3. Whether competitors can design around the claimed excipient system.
4. Whether the patent survives obviousness and enablement challenges.
5. Whether the patent term extends beyond regulatory and market launch timing.

A patent covering only a broad list of polymers may have limited defensive value. A patent tied to measurable dissolution ranges, a defined multilayer structure, or a difficult manufacturing sequence may create stronger practical barriers.

What manufacturing and IP barriers matter most?

The critical manufacturing barrier is controlled release at commercial scale. Laboratory release profiles can change after scale-up because of differences in:

• Granule density
• Polymer hydration
• Compression force
• Tablet porosity
• Lubrication
• Coating weight gain
• Blend segregation
• Equipment shear

Moisture management is also important. Pseudoephedrine hydrochloride and naproxen sodium must remain chemically stable while the matrix retains consistent hydration and mechanical properties. Packaging may require high-barrier bottles or blister systems with desiccant protection, depending on stability data.

IP barriers may attach to the process rather than the ingredient list. A competitor can often match a qualitative excipient declaration but still struggle to reproduce the same performance without infringing a process or release-profile claim.

Which licensing and partnership opportunities exist?

The most attractive licensing targets are usually excipient platforms rather than the active ingredients.

Potential partners include:

• Controlled-release polymer suppliers
• Coprocessed excipient manufacturers
• Contract development and manufacturing organizations
• OTC brand owners
• Retail private-label operators
• Packaging suppliers with pseudoephedrine compliance infrastructure
• Companies with abuse-deterrent or tamper-resistant technology

A licensing transaction may be structured around:

• Regional rights
• Product-specific rights
• Technology access
• Manufacturing know-how
• Supply commitments
• Milestone payments
• Royalty on net sales
• Minimum annual volumes

A polymer supplier with established regulatory support and a Drug Master File can reduce development time. A CDMO with validated extended-release processes can reduce scale-up risk. A brand owner can provide retail distribution and consumer recognition, which may be more valuable than a narrow formulation patent in a mature OTC category.

How does the product compare with competing sinus and cold formulations?

Product type	Pain relief	Nasal decongestion	Dosing convenience	Key limitation
Naproxen sodium plus pseudoephedrine ER	Strong and long-acting	Long-acting	Typically 12-hour	Cardiovascular and NSAID warnings
Ibuprofen plus pseudoephedrine	Strong analgesia	Often extended release	Often 12-hour	Different NSAID tolerability profile
Acetaminophen plus pseudoephedrine	Pain and fever relief	Immediate or extended release	Varies	No anti-inflammatory effect
Separate naproxen and pseudoephedrine	Flexible dosing	Flexible dosing	Lower convenience	More complex regimen
Multi-ingredient cold product	Broad symptom coverage	Often included	Convenient	Greater interaction and duplication risk

The combination has a clear positioning advantage for consumers seeking both anti-inflammatory pain relief and sustained decongestion. Its principal disadvantage is the combined warning burden. Patients with hypertension, cardiovascular disease, gastrointestinal ulcer risk, renal impairment, or NSAID sensitivity may require alternative products.

What are the commercial opportunities?

The market opportunity is concentrated in differentiation rather than new active-ingredient discovery.

Private-label and retailer products

Retailers can offer store-brand versions using the same active strengths and a lower-cost excipient system. The main value drivers are:

• Lower tablet and packaging cost
• Reliable pseudoephedrine supply
• Consistent 12-hour dissolution
• Retail compliance
• High-volume contract manufacturing

Smaller and easier-to-swallow tablets

A high-density matrix or multilayer design could reduce tablet bulk. This has consumer value because the combined active load is substantial. A smaller tablet may support premium positioning if the release profile remains equivalent.

Alternative dosage forms

Multiparticulate capsules, coated mini-tablets, and sachets could support:

• Easier swallowing
• Flexible dose titration
• Taste-masked administration
• Pediatric or adolescent development, subject to regulatory and safety restrictions

These formats carry greater development and packaging costs and may not be justified for a standard adult OTC indication.

Premium packaging and adherence

A 12-hour regimen supports blister calendars, unit-dose packaging, and travel packs. Packaging can differentiate the product without changing the active ingredients. Child-resistant, tamper-evident, and pseudoephedrine-compliant designs may become part of the commercial proposition.

Revenue exposure

Revenue is exposed to low-cost generic and private-label substitution, retailer negotiation, pseudoephedrine regulation, and seasonal demand. A brand owner can defend price through dosing convenience, recognized branding, packaging, and reliable availability. Public-company revenue attributable specifically to this combination is generally not disclosed separately, so product-level revenue estimates should not be inferred from overall corporate OTC sales.

Is there biosimilar risk?

There is no biosimilar risk. Naproxen sodium and pseudoephedrine hydrochloride are chemically synthesized small molecules. Competition arises from generic, OTC monograph, private-label, and authorized-generic pathways rather than biosimilar applications.

Key Takeaways

• The core formulation challenge is controlling pseudoephedrine hydrochloride release while preserving naproxen sodium dissolution.
• A hypromellose-based hydrophilic matrix is the lowest-complexity development platform for a 12-hour tablet.
• Multilayer and multiparticulate systems offer stronger differentiation but increase manufacturing and regulatory complexity.
• Active-ingredient patent protection is not the main barrier; formulation know-how, trademarks, retail access, and pseudoephedrine compliance are more important.
• Generic and private-label entry risk is high because both active ingredients are mature and widely sourced.
• The strongest commercial opportunities are private-label supply, smaller tablets, premium packaging, controlled-release excipient licensing, and high-volume CDMO partnerships.
• Biosimilar risk does not apply.
• Any launch or licensing decision requires a current product-specific review of FDA databases, Orange Book entries, patents, trademarks, and litigation records.

FAQs

Can naproxen sodium and pseudoephedrine hydrochloride be formulated as a single immediate-release tablet?

Yes, but the combination would not provide the same 12-hour decongestant profile. A single immediate-release product would require more frequent dosing and could increase peak-related tolerability concerns for pseudoephedrine.

Which excipient is most suitable for pseudoephedrine extended release?

Hypromellose is the most conventional starting point because it has broad pharmaceutical use, scalable processing options, and established regulatory familiarity. The correct grade and concentration must be determined through dissolution and stability development.

Does pseudoephedrine require special packaging?

The product must comply with federal and state controls applicable to pseudoephedrine sales. Packaging and distribution systems should support retail purchase controls, inventory tracking, and applicable quantity limits.[3]

Can a competitor copy the inactive ingredient list?

A competitor may be able to use similar inactive ingredients, but matching the release profile, stability, tablet mechanics, and manufacturing performance can remain difficult. Patent claims, trade secrets, and process controls may limit practical replication.

Is a chewable naproxen sodium and pseudoephedrine product commercially attractive?

It could provide a differentiated dosage form, but taste masking, dose size, pseudoephedrine exposure, and consumer safety labeling create substantial development requirements. The opportunity is stronger for a targeted niche than for an immediate mass-market replacement of a conventional tablet.

References

1. DailyMed. (n.d.). Naproxen sodium and pseudoephedrine hydrochloride extended-release tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2023). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.fda.gov/

3. U.S. Drug Enforcement Administration. (n.d.). Combat methamphetamine epidemic provisions and pseudoephedrine retail requirements. https://www.deadiversion.usdoj.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/